osi 774

Erlotinib (CP358774) 是一种 EGFR 一代抑制剂，抑制 EGFR 19 Del 和 L858R 突变。Erlotinib 具有抗肿瘤活性，用于治疗 EGFR 突变的非小细胞肺癌。Erlotinib 用药会产生 EGFR C797S 耐药突变。

Erlotinib hydrochloride (NSC 718781) 抑制EGFR 激酶的IC50为 2 nM，用于治疗非小细胞肺癌。

Erlotinib is an epidermal growth factor receptor inhibitor. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor.

Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib .

Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib D6 hydrochloride a deuterium labeled Erlotinib Hydrochloride.